Publications

CSET produces evidence-driven analysis in a variety of forms, from informative graphics and translations to expert testimony and published reports. Our key areas of inquiry are the foundations of artificial intelligence — such as talent, data and computational power — as well as how AI can be used in cybersecurity and other national security settings. We also do research on the policy tools that can be used to shape AI’s development and use, and on biotechnology.

Analysis

Chinese Critiques of Large Language Models

William Hannas, Huey-Meei Chang, Maximilian Riesenhuber, and Daniel Chou
| January 2025

Large generative models are widely viewed as the most promising path to general (human-level) artificial intelligence and attract investment in the billions of dollars. The present enthusiasm notwithstanding, a chorus of ranking Chinese scientists regard this singular approach to AGI as ill-advised. This report documents these critiques in China’s research, public statements, and government planning, while pointing to additional, pragmatic reasons for China’s pursuit of a diversified research portfolio.

Compete


Peer Watch


Filter publications
Formal Response

CSET’s Recommendations for an AI Action Plan

March 14, 2025

In response to the Office of Science and Technology Policy's request for input on an AI Action Plan, CSET provides key recommendations for advancing AI research, ensuring U.S. competitiveness, and maximizing benefits while mitigating risks. Our response highlights policies to strengthen the AI workforce, secure technology from illicit transfers, and foster an open and competitive AI ecosystem.

Formal Response

RFI Response: Safety Considerations for Chemical and/or Biological AI Models

Steph Batalis and Vikram Venkatram
| December 3, 2024

Dr. Steph Batalis and Vikram Venkatram offered the following comment in response to the National Institute of Standards and Technology's request for information on safety considerations for chemical and biological AI models.

Artificial intelligence (AI) tools pose exciting possibilities to advance scientific, biomedical, and public health research. At the same time, these tools have raised concerns about their potential to contribute to biological threats, like those from pathogens and toxins. This report describes pathways that result in biological harm, with or without AI, and a range of governance tools and mitigation measures to address them.

Analysis

China and Medical AI

Caroline Schuerger, Vikram Venkatram, and Katherine Quinn
| May 2024

Medical artificial intelligence, which depends on large repositories of biological data, can improve public health and contribute to the growing global bioeconomy. Countries that strategically prioritize medical AI could benefit from a competitive advantage and set global norms. This report examines China’s stated goals for medical AI, finding that the country’s strategy for biodata collection and medical AI development positions it to be an economic and technological leader in this sector.

Analysis

China, Biotechnology, and BGI

Anna Puglisi and Chryssa Rask
| May 2024

As the U.S. government considers banning genomics companies from China, it opens a broader question about how the United States and other market economies should deal with China’s “national champions.” This paper provides an overview of one such company—BGI—and how China’s industrial policy impacts technology development in China and around the world.

Other

AI and Biorisk: An Explainer

Steph Batalis
| December 2023

Recent government directives, international conferences, and media headlines reflect growing concern that artificial intelligence could exacerbate biological threats. When it comes to biorisk, AI tools are cited as enablers that lower information barriers, enhance novel biothreat design, or otherwise increase a malicious actor’s capabilities. In this explainer, CSET Biorisk Research Fellow Steph Batalis summarizes the state of the biorisk landscape with and without AI.

Data Brief

The Antimicrobial Resistance Research Landscape and Emerging Solutions

Vikram Venkatram and Katherine Quinn
| November 2023

Antimicrobial resistance (AMR) is one of the world’s most pressing global health threats. Basic research is the first step towards identifying solutions. This brief examines the AMR research landscape since 2000, finding that the amount of research is increasing and that the U.S. is a leading publisher, but also that novel solutions like phages and synthetic antimicrobial production are a small portion of that research.

Formal Response

Comment on OSTP RFI 88 FR 60513

Steph Batalis
| October 16, 2023

CSET submitted the following comment in response to a Request for Information (RFI) from the White House's Office of Science and Technology Policy about potential changes to the Policies for Federal and Institutional Oversight of Life Sciences Dual Use Research of Concern (DURC) and Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight (P3CO).

Analysis

Understanding the Global Gain-of-Function Research Landscape

Caroline Schuerger, Steph Batalis, Katherine Quinn, Ronnie Kinoshita, Owen Daniels, and Anna Puglisi
| August 2023

Gain- and loss-of-function research have contributed to breakthroughs in vaccine development, genetic research, and gene therapy. At the same time, a subset of gain- and loss-of-function studies involve high-risk, highly virulent pathogens that could spread widely among humans if deliberately or unintentionally released. In this report, we map the gain- and loss-of-function global research landscape using a quantitative approach that combines machine learning with subject-matter expert review.

Analysis

A Shot of Resilience

Steph Batalis and Anna Puglisi
| May 2023

Vaccines keep the U.S. public healthy while safeguarding economic stability and biosecurity. This report assesses the domestic vaccine manufacturing landscape and identifies two major vulnerabilities: a reliance on foreign manufacturers and a lack of manufacturing redundancy. Maintaining a resilient vaccine supply will require the U.S. government to take steps to protect the existing supply, identify and monitor manufacturing vulnerabilities, and create a stronger domestic production base.